About Zechems

For more than 30 years, our primary field of interest has been the development of innovative, patient-centric technology that effectively delivers therapies to patients with Parkinson’s disease. We work with specialist focus groups, fund clinical trials and invest in care initiatives that optimise treatment programmes and improve quality of life.

Founded in 1982 as a small, family-run business specialising in niche therapies, Zechems have experienced successful growth to become a global speciality pharmaceutical centre of excellence. We continue to redefine and innovate drug delivery methods for Parkinson’s and other disorders, and are committed to combining research and development excellence with world-class patient care, through caring for peoples health as a trusted partner.

Zechems puts its people at the heart of everything we do and ensures that our values and behaviours are lived every day. Zechems grew a lot the last few years and will continue to do so into new markets which makes it an exciting time to join the company!

#
#

Therapeutic Focus

Zechems Pharmaceuticals Plc is dedicated to improving the lives of people with long-term neurological conditions, and providing important support for their families, caregivers, and medical teams.

We offer world-leading medications to improve disease management and quality-of-life for patients, as well as supporting treatment programmes for patients, families, and carers that provide extra assistance in managing these conditions.

ZECHEMS PHARM PLC Over 30 years experience

We have over 30 years’ experience in movement disorder specialties. We work collaboratively with partners across the world to ensure that our patients the right treatment, at the right time.

Research and Development investment accelerated...!

#

Carbon Footprint Statement

Zechems Pharmaceuticals Plc acknowledge that there is a pressing need to dramatically and urgently reduce global carbon emissions to prevent irreversible climate change. We are determined to play our part in this respect and reduce the carbon emissions attributable to our organisation.

Zechems have carried out a thorough and independent Carbon analysis of all activities attributable to our business

#

Investigator Initiated Research (IIR)

We are committed to delivering innovative therapies to our patients throughout the world. We believe in the need for innovative clinical research to be conducted, which addresses important medical and scientific questions for our therapeutic areas of interest.

Investigator submits IIR concept proposal to Zechems Pharmaceuticals Ltd

#
#

Small Molecule

For more than 30 years, we have delivered comprehensive small molecule API development and manufacturing solutions to leading pharmaceutical and biotechnology organisations

#

API Manufacturing at Zechems

The rapid pace of innovation in small molecule development today calls for an equally dynamic approach to API manufacturing

#

24 Hours CMC Supports

Our CMC services team is wholly dedicated to ensuring your product and process’ quality and compliance.

Science & Innovation

  • Clinical Trials

    We work with specialist focus groups, fund clinical trials and invest in care initiatives that optimise treatment programmes and improve quality of life.

  • Scientific Advisors

    We take advice from internationally renowned experts, with vast experience in our therapy areas. Our advisors provide consultancy to Zechems Pharmaceuticals, which allows us to prioritize our research to ensure optimal outcomes for patients, their caregivers and healthcare providers.

  • Our Innovations

    We are dedicated to improving the lives of people with long-term neurological conditions, and providing important support for their families, caregivers, and medical teams.

  • Collaboration

    We provide valuable consultancy, which ensures that we are providing up-to-date information for healthcare provider, for caregivers, and for patients.

  • Our Commitment

    At Zechems, we work with specialist focus groups and fund clinical trials to ensure that treatment programmes are optimised and that quality of life is improved. We are committed to ensuring that any clinical trial we fund is patient centric and centred around improving quality of life in our therapeutic focus area.

#

Welcome to Zechems Pharmaceuticals Plc


Study the Diseases


Research


Invent New Drugs


Quality Assurance

Therapy Areas

Parkinson’s Disease


Parkinson’s disease is a progressive neurodegenerative condition that occurs when some of the cells in the brain (neurons) stop working properly and are lost over time. People with Parkinson’s disease typically have movement-related (motor) problems like shaking, rigidity and difficulty walking.

Schizophrenia


Schizophrenia is a long-term severe mental health condition that causes a range of psychological symptoms. It is often described as a type of psychosis where people are not always able to distinguish thoughts and ideas from reality.

Our Nurse Service


Our dedicated nursing team, founded in 2008, works closely with healthcare professionals in the community to provide specialist care to patients with Parkinson’s disease and Schizophrenia.

Contact us

Speak to our team

Our team are available to assist with your enquiry. If you would like to contact us directly, please use:

115, Selsdon Road, South Croydon cr2 a3, United Kingdom..

+44 74 357 508 43

info@zechems-pharm.com

If you have a media-based query, please contact us directly: